Insmed (INSM) Projected to Post Quarterly Earnings on Thursday

Key Points

• Insmed is expected to report Q3 2026 results before the market opens on October 29, with analysts projecting a loss of $0.3879 per share and revenue of approximately $499.1 million.
• The company beat expectations in its prior quarter, reporting a $0.06-per-share loss versus the estimated $0.67 loss, while revenue surged 296.1% year over year to $425.5 million.
• Insmed shares recently traded at $94.04, down 1.7%, while analysts maintain a “Moderate Buy” consensus and an average price target of $198.91.

Insmed (NASDAQ:INSM - Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Insmed to post earnings of ($0.3879) per share and revenue of $499.06 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Insmed (NASDAQ:INSM - Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm had revenue of $425.49 million for the quarter, compared to analyst estimates of $395.50 million. During the same quarter in the prior year, the business posted ($1.70) EPS. The business's revenue was up 296.1% compared to the same quarter last year. On average, analysts expect Insmed to post ($1.72) EPS for the current fiscal year and $1.01 EPS for the next fiscal year.

Insmed Stock Down 1.7%

Shares of INSM opened at $94.04 on Thursday. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74. Insmed has a 12 month low of $90.39 and a 12 month high of $212.75. The firm's 50 day moving average is $116.48 and its 200-day moving average is $116.57. The stock has a market capitalization of $20.54 billion, a PE ratio of -22.88 and a beta of 0.83.

Analysts Set New Price Targets

A number of brokerages recently issued reports on INSM. Raymond James Financial set a $173.00 price target on Insmed in a research report on Tuesday. Jefferies Financial Group restated a "buy" rating and set a $175.00 price objective on shares of Insmed in a research note on Thursday, August 6th. BMO Capital Markets reaffirmed an "outperform" rating on shares of Insmed in a report on Tuesday, October 6th. The Goldman Sachs Group began coverage on Insmed in a research report on Thursday, September 24th. They set a "buy" rating and a $188.00 target price for the company. Finally, Roth Capital reissued a "buy" rating and set a $198.00 target price (down from $212.00) on shares of Insmed in a report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $198.91.

Insider Buying and Selling at Insmed

In other Insmed news, COO Roger Adsett sold 239,850 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the completion of the sale, the chief operating officer directly owned 98,744 shares in the company, valued at $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Brennan sold 25,000 shares of the firm's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares in the company, valued at approximately $4,865,512. This represents a 38.92% decrease in their position. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by corporate insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed's lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.